BILL ANALYSIS
SB 1106
Page 1
Date of Hearing: August 4, 2010
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Felipe Fuentes, Chair
SB 1106 (Yee) - As Amended: April 5, 2010
Policy Committee: Health Vote:11-6
Business & Professions 6-4
Urgency: No State Mandated Local Program:
Yes Reimbursable: No
SUMMARY
This bill requires a prescriber dispensing a drug sample or
starter kit to either provide the patient with a copy of the
Federal Drug Administration (FDA)-approved package insert for
the drug sample or starter kit or ensure the drug manufacturer's
warnings are affixed to the package containing the sample or
starter kit.
FISCAL EFFECT
No direct fiscal impact to the California Board of Pharmacy or
the Medical Board of California.
COMMENTS
1)Rationale . According to the author, this bill ensures adequate
information is provided to patients who receive free samples
of prescription drugs. The dispensing of free medications is a
common practice, but patients do not always receive adequate
written information about risks and medication management.
This bill increases the specificity of what must be provided
to patients by providers prescribing free samples or starter
kits.
2)Background . Under current law, a variety of health
professionals are authorized to dispense free drug samples.
The samples may be provided if they are in the package
provided by the manufacturer and a related notation is entered
into the patient's chart. Pharmaceutical companies use
medication samples as a promotional tool. According to
industry data, millions of medications and billions of dollars
SB 1106
Page 2
worth of prescription drugs were dispensed in 2007. For
example, Pfizer dispensed more than $2.5 billion, Merck
dispensed $350 million, and Eli Lilly and Wyeth each dispensed
more than $50 million in drug samples.
3)Concerns . The California Medical Association (CMA) is
concerned this bill will make it more difficult for physicians
to provide free samples to patients.
4)Related Legislation . AB 2690 (Krekorian) in 2008 would have
assigned some responsibility for warning patients about
hazards and risks of medications to the drug manufacturer. The
bill was placed on the inactive file of the Assembly. Under
current law the drug manufacturer has no responsibility to
warn patients about medication risks if adequate information
has been provided to the prescriber.
Analysis Prepared by : Mary Ader / APPR. / (916) 319-2081